Earn CME Credits: Improve Patient Care in Acute Myeloid Leukemia with Medscape
- Medscape, LLC and the American Society of Hematology developed this CME activity to improve patient care.
- This Journal-based CME activity offers a maximum of 1.0 AMA PRA Category 1 Credit(s)™.
- Completing this CME activity, including the evaluation component, allows participants to earn up to 1.0 MOC points in the ABIM Maintenance of Certification program.
Medscape offers continuing medical education (CME) online.
Medscape, LLC and the American Society of Hematology developed this CME activity to improve patient care. Medscape, LLC is accredited by the ACCME, ACPE, and ANCC to provide continuing education for healthcare teams.
This Journal-based CME activity offers a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should only claim the credit that matches their level of participation.
Completing this CME activity, including the evaluation component, allows participants to earn up to 1.0 MOC points in the ABIM Maintenance of Certification program. The CME provider is responsible for submitting completion information to the ACCME for ABIM MOC credit.
Other clinicians will receive a certificate of participation. To participate in this CME activity, follow these steps: (1) review learning objectives; (2) study the educational content; (3) take the post-test, scoring at least 75%, and complete the evaluation at https://www.medscape.org/journal/blood; (4) view or print your certificate. For CME questions, see page 2271.
Disclosures
Laurie Barclay, freelance writer and reviewer for Medscape, LLC, has no competing financial interests.
Learning Objectives
After completing this activity, participants will be able to:
- Explain classifications and outcomes using the 2022 European Leukemia Net (ELN) prognostic criteria. This is based on a pooled analysis of patients with newly diagnosed acute myeloid leukemia (AML) from the phase 3 VIALE-A trial (NCT02993523) and phase 1b study (NCT02203773).
- Analyze the prognostic significance of different genetic factors among patient subgroups, particularly those benefiting from venetoclax-azacitidine, utilizing new molecular signatures derived from bioinformatics. This is also based on data from the same trials.
- Identify the clinical implications of the 2022 ELN risk classifications compared to bioinformatic-derived molecular signatures for predicting overall survival in newly diagnosed AML patients.
Release date: November 21, 2024; Expiration date: November 21, 2025.